Photonics and nanomaterials could detect cancer signals five to eight years before diagnosis

Seemesh Bhaskar, a postdoctoral researcher in Brian Cunningham's Nanosensors Group at the University of Illinois, believes the most important cancer diagnosis is the one that happens before the cancer exists. Not in a metaphorical sense - in a literal, molecular one.

The research he and Cunningham recently published in Chemical Reviews - the highest-impact-factor journal in chemistry - lays out how photonics and nanotechnology could detect molecular signals associated with cancer development five to eight years before current diagnostic tools would flag anything abnormal.

The logic of early molecular signals

Cancer begins with errors in DNA and RNA. Mutations accumulate, gene expression shifts, and the cellular machinery gradually tilts toward uncontrolled growth. Long before a tumor is visible on imaging or a patient develops symptoms, the body produces microRNAs - small RNA fragments that regulate gene expression and can serve as early indicators that something has gone wrong at the molecular level.

The problem is detection. These molecules are tiny, present in vanishingly small quantities during early disease stages, and invisible to conventional instruments. Standard diagnostic tools - blood tests, imaging, biopsies - are designed to catch cancer once it has already established itself, not while it is still a possibility encoded in scattered molecular signals.

Where photonics comes in

Nanomaterials are small enough to interact with microRNA directly. Light and nanomaterials interact with each other, and nanomaterials can also interact with biological systems. By engineering photonic substrates - surfaces designed to manipulate light at the nanoscale - and combining them with carefully constructed nano-assemblies, the Illinois team created a system that can detect microRNA at concentrations far below what conventional instruments achieve.

The technical innovation, according to Bhaskar, involves tapping into a property of light that researchers had largely ignored for decades: its magnetic flux. Light is electromagnetic radiation, carrying both electric and magnetic components. Most photonic research has focused on the electric field because the magnetic component was considered inaccessible with available tools. Bhaskar's team engineered nano-assemblies in the laboratory that could interact with the magnetic flux, opening a new detection channel.

A century of overlooked physics

The Chemical Reviews paper, representing more than two years of work, includes extensive reviews of discoveries from 1900 to 1980 to build the case for why the gap between cancer's initial development and its formal diagnosis has persisted. The historical analysis argues that the tools simply did not exist to detect the earliest molecular signals - and that by the time they did, the research community had already organized itself around later-stage detection.

Bhaskar and Cunningham's approach inverts that paradigm. Rather than waiting for a tumor to grow large enough to see, they look for the microRNA signals that predict its growth. If validated in clinical settings, the approach could give physicians years of additional lead time - and more lead time means more treatment options and better outcomes.

What has not been proven yet

This is a review paper, not a clinical trial. The five-to-eight-year detection advantage is a theoretical projection based on the sensitivity of the photonic detection system and the known timelines of cancer development, not a demonstrated clinical outcome. No patient has been diagnosed earlier using this specific technology.

Moving from laboratory detection of microRNA in controlled samples to reliable early cancer screening in real patients involves enormous challenges: standardizing the nano-assembly fabrication, validating detection accuracy across different cancer types, distinguishing cancer-associated microRNA from microRNA produced by other conditions, and conducting prospective clinical studies that follow patients long enough to confirm that early detection actually changes outcomes.

The specificity question is particularly important. MicroRNAs are involved in many biological processes, not just cancer. A detection system sensitive enough to find trace quantities must also be specific enough to avoid false positives, which could trigger unnecessary anxiety and invasive follow-up procedures.

Still, the underlying physics is sound, the detection sensitivity is real, and the need for earlier cancer detection is undeniable. Whether this particular approach bridges the gap from laboratory promise to clinical utility will depend on the next phase of research - work that Cunningham's lab at Illinois is well positioned to pursue.